87503 Infectious agent detection by nucleic acid (DNA or RNA); influenza virus, for multiple types or sub-types, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, each additional influenza virus type or sub-type

Name of the Procedure:

Infectious Agent Detection by Nucleic Acid (DNA or RNA); Influenza Virus, for Multiple Types or Sub-types
Common Names: Influenza Virus Testing, Multiplex PCR Test for Influenza, Influenza Sub-typing

Summary

This procedure involves detecting the presence of influenza viruses in a patient's sample using advanced genetic testing methods. By analyzing the DNA or RNA of the virus, multiple types or sub-types of influenza can be identified. This test often employs multiplex reverse transcription and amplified probe techniques to ensure accurate and efficient results.

Purpose

This test is used to diagnose influenza infections, determine the specific type or subtype of the influenza virus, and guide appropriate treatment. It helps in understanding the prevalent strains of influenza in a population and can assist in public health surveillance and outbreak management.

Indications

• Symptoms such as fever, cough, sore throat, body aches, and fatigue that suggest influenza.
• Severe respiratory illness or complications suspected to be caused by influenza.
• Patients at high risk for influenza complications, such as the elderly, young children, pregnant women, or those with chronic illnesses.
• Outbreak investigations in community settings like schools, nursing homes, or hospitals.

Preparation

• Generally, no special preparation is required for the test.
• Patients should inform their healthcare provider of all medications they are taking.
• In some cases, it may be necessary to avoid certain medications that could interfere with the test results.

Procedure Description

1. Sample Collection: Typically, a nasal or throat swab is taken from the patient. Sometimes, other respiratory samples like sputum can be used.
2. Reverse Transcription: If RNA viruses are being tested, the RNA is converted to DNA using reverse transcription.
3. Multiplex PCR Amplification: Multiple DNA sequences specific to different influenza types or sub-types are simultaneously amplified.
4. Detection: The amplified DNA sequences are then identified and quantified, indicating the presence and specific type or subtype of the influenza virus.

Duration

The entire process from sample collection to receiving results usually takes a few hours to a day, depending on the laboratory's processing time.

Setting

This procedure is typically performed in a clinical laboratory setting. The sample collection can take place in various settings, including hospitals, outpatient clinics, and doctors' offices.

Personnel

• Trained healthcare providers (e.g., nurses or medical assistants) collect the sample.
• Medical laboratory technologists or scientists perform the analysis in the lab.
• Pathologists or microbiologists interpret the results.

Risks and Complications

• Sample Collection: Mild discomfort, gagging, or irritation at the sample collection site.
• Laboratory Analysis: Minimal risk as it is conducted on the specimen isolated from the patient; no direct risks to the patient.

Benefits

• Accurate identification of the influenza virus type or subtype.
• Helps in determining the appropriate antiviral treatment.
• Aids in infection control and public health measures.
• Results are typically available rapidly, aiding in quick decision-making.

Recovery

• No specific recovery required from the test itself.
• Patients should follow their healthcare provider's advice based on the test results.
• Further medical treatment will depend on the diagnosis.

Alternatives

• Rapid Influenza Diagnostic Tests (RIDTs): Provide quicker results but are less accurate.
• Viral Culture: More accurate but takes longer to obtain results.
• Immunofluorescence Detection: Can detect influenza but requires specialized equipment.

Patient Experience

• During the Procedure: Patients may feel temporary discomfort or a gagging sensation during nasal or throat swab collection.
• After the Procedure: No significant aftereffects from the test itself.
• Pain management is typically not necessary as the procedure is minimally invasive.

Patients are advised to communicate any discomfort or concerns to their healthcare provider, who can provide reassurance and additional information.